Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab with paclitaxel or carboplatin-cyclophosphamide in first-line advanced triple-negative breast cancer
NL-OMON60745Phase 2Active, not recruiting
- Sponsor
- Borstkanker Onderzoek Groep
- Start
- Oct 2013
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab, paclitaxel, carboplatin, cyclophosphamide in triple-negative breast cancer (TNBC), sponsored by Borstkanker Onderzoek Groep. Started Oct 2013; status: active, not recruiting.
02
Drugs
atezolizumabpaclitaxelcarboplatincyclophosphamide
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NL-OMON60745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60745.